
The biotechnology sector has officially recovered after it stumbled into bear market territory after major biotech indexes plummeted during the second half of 2015.﻿﻿ ﻿﻿ The sector fell by 13% in just four days in late September, dropping more than 45% before finding a bottom. 
 
Highly risk-tolerant investors who believe biotechnology will continue to grow in 2020 should consider mutual funds that have a high portfolio allocation to the biotech sector. These mutual funds provide professionally managed exposure to the sector and help minimize costs while investing in many stocks related to biotech, pharmaceuticals, and healthcare.
 
The fund seeks capital appreciation by investing primarily in companies involved in biotechnology-related activities. Under normal market conditions, the Fidelity Select Biotechnology Portfolio invests at least 80% of its total net assets of common stocks of companies involved in research, development, manufacturing, and distribution of various biotech products and services.﻿﻿ The Fidelity Select Biotechnology Portfolio's top industry allocations are 91.47% to biotech and 4.90% to pharmaceuticals.﻿﻿
 
Fidelity Investments issued the Fidelity Select Biotechnology Portfolio on Dec. 16, 1985. As of October 24, 2018, the fund has achieved a 10-year average annual return of 15.33% and has total portfolio assets of $5.796 billion. Additionally, it has a one-year return of -3.38%. The fund has no minimum investment requirement and charges an annual net expense ratio of 0.72%.﻿﻿
 
The T. Rowe Price Health Sciences Fund seeks to provide long-term capital appreciation by investing at least 80% of its total net assets in common stocks of companies involved in research, development, production, and distribution of products and services related to the health care, medicine, and life sciences sectors.﻿﻿ ﻿﻿
 
The T. Rowe Price Health Sciences Fund was issued on Dec. 29, 1995, and currently manages $11.6 billion. As of April 30, 2018, it has generated a trailing total return for a 10-year period of 16.4%. The fund has a YTD return of 0-3.7%. A minimum investment of $2,500 is required to invest in the fund, with an annual expense ratio of 0.77%.﻿﻿
 
While the T. Rowe Price Health Sciences Fund does not provide full exposure to the biotech sector, its top 10 holdings, equal to 32.77%, contain familiar names in healthcare such as UnitedHealth Group Inc., Eli Lilly, and Vertex Pharmaceuticals.﻿﻿ 
 
The fund is a pure biotechnology fund; it allocates 94.13% of its total net assets to the biotech sector and 4.04% to the pharmaceuticals sector. As of October 24, 2018, the Fidelity Advisor Biotechnology Fund has total net assets of $1.830 billion. Under normal circumstances, the fund invests at least 80% of its total net assets in common stocks of companies involved in developing, researching, manufacturing and distributing biotech-related products and services, as well as companies that benefit from advances in the biotech sector.﻿﻿
 
The Fidelity Advisor Biotechnology Fund - Class A was issued on Dec. 27, 2000, by Fidelity Investments. As of April 30, 2020, the fund has a YTD return of 2.84%, with an average five-year return of -0.03% and an average 10-year return of 15.14%. The fund charges an annual net expense ratio of 1.04% and does not have a minimum initial investment requirement.﻿﻿ ﻿﻿
 
The Janus Global Life Sciences Fund seeks to provide long-term capital appreciation by taking a balanced approach to investing across sub-sectors of companies that the portfolio manager deems to be related to the life sciences sector. The company invests in life science and biotech companies such as Merck and Co., Novartis AG, Humana Inc., AstraZeneca PLC, and others.﻿﻿ 
 
The Janus Global Life Sciences Fund was issued on Dec. 31, 1998, by Janus Capital Group. The fund charges an annual net expense ratio of 0.77%. As of October 24, 2018, the fund has a YTD return of -13.61%, a five-year average return of 3.73%, and the 10-year average return of 14.83%. The fund stewards $3.42 billion AUM.﻿﻿
 
The fund's objective is to provide investors with long-term capital appreciation. The fund attempts to achieve its objective by investing at least 80%, under normal market conditions, of its total net assets in common stocks of biotechnology and discovery research companies.﻿﻿ The fund's top allocations are 77.11% to biotechnology, 11.10% to pharmaceuticals, and 7.07% to cash & cash equivalents.﻿﻿
 
The Franklin Biotechnology Discovery Fund was issued on Sept. 15, 1997, by Franklin Templeton Investments. The fund charges an annual net expense ratio of 1.02% and requires a minimum investment of $1,000. As of April 30, 2020 the fund has generated a 10-year average annualized return of 12.66% and an average annualized return of -3.12% for the past five years.﻿﻿ 
 Yahoo! Finance. "SPDR S&P Biotech ETF (XBI)." Accessed April 28, 2020. Yahoo! Finance. "iShares Nasdaq Biotechnology ETF (IBB)." Accessed April 28, 2020. Fidelity. "Fidelity® Select Biotechnology Portfolio." Accessed April 28, 2020. Fidelity. "Fidelity® Select Biotechnology Portfolio–Composition." Accessed April 28, 2020. T.RowePrice. "Health Sciences Fund Prospectus," Page 2. Accessed April 28, 2020. T.RowePrice. "Health Sciences Fund." Accessed April 30, 2020. T.RowePrice. "Health Sciences Fund–Holdings." Accessed April 30, 2020. Fidelity. "Fidelity Advisor Biotechnology Fund - Class A–Fees & Distribution." Accessed April 30, 2020. Fidelity. "Fidelity Advisor Biotechnology Fund - Class A." Accessed April 30, 2020. Jaus Henderson. "Global Life Sciences Fund Fact Sheet," Pages 1-2. Accessed April 28, 2020. Janus Henderson. "Global Life Sciences Fund." Accessed April 30, 2020. Franklin Templeton. "Franklin Biotechnology Discovery Fund." Accessed April 30, 2020. Franklin Templeton. "Franklin Biotechnology Discovery Fund–Portfolio." Accessed April 30, 2020.